Effect of combined sedation using multiple drugs on inflammatory cytokines in patients with acute respiratory distress syndrome
DOI:
https://doi.org/10.1590/s2175-97902023e21461Keywords:
Acute respiratory distress syndrome; Combined sedation; Propofol; Midazolam; Dexmedetomidine; Cytokines, Acute respiratory distress syndrome, Combined sedation, Propofol, Midazolam, Dexmedetomidine, CytokinesAbstract
The innate immune response plays an important role in the pathophysiology of acute respiratory distress syndrome (ARDS); however, no drug has been proven to be beneficial in the management of ARDS. Therefore, the aim of this study was to investigate the effects of using combined sedatives on systemic inflammatory responses in patients with ARDS. A total of 90 patients with ARDS and an intubation time of > 120 h were randomly divided into the propofol group (group P), midazolam group (group M), and combined sedation group (group U). Patients in groups P and M were sedated with propofol and midazolam, respectively, whereas patients in group U were sedated with a combination of propofol, midazolam, and dexmedetomidine. The dosage of sedatives and vasoactive drugs, duration of mechanical ventilation, and incidence of sedative adverse reactions were documented. The dosage of sedatives and vasoactive drugs, as well as the incidence of sedative adverse reactions in group U, was significantly lower than those in groups P and M. Similarly, the duration of mechanical ventilation in group U was significantly shorter than that in groups P and M. Hence, inducing sedation through a combination of multiple drugs can significantly reduce their adverse effects, improve their sedative effect, inhibit systemic inflammatory responses, and improve oxygenation in patients with ARDS.
Downloads
References
Amini A, Arhami Dolatabadi A, Kariman H, Hatamabadi H, Memary E, Salimi S, et al. Low-dose fentanyl, propofol, midazolam, ketamine and lidocaine combination vs. regular dose propofol and fentanyl combination for deep sedation induction; a randomized clinical trial. Emerg (Tehran). 2018;6(1):e57.
Angsuwatcharakon P, Rerknimitr R, Ridtitid W, Kongkam P, Poonyathawon S, Ponauthai Y, et al. Cocktail sedation containing propofol versus conventional sedation for ERCP: a prospective, randomized controlled study. BMC Anesthesiol. 2012;12:20.
Chen X, Hu J, Zhang C, Pan Y, Tian D, Kuang F, et al. [Effect and mechanism of dexmedetomidine on lungs in patients of sepsis complicated with acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018;30(2):151-5.
Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-73.
Grawe ES, Bennett S, Hurford WE. Early paralysis for the management of ARDS. Respir Care. 2016;61(6):830-8.
Guo F, Ding Y, Yu X, Cai X. Effect of dexmedetomidine, midazolam, and propofol on lipopolysaccharide-stimulated dendritic cells. Exp Ther Med. 2018;15(6):5487-94.
Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth. 2019;122(4):448-59.
Kallet RH. Should PEEP titration be based on chest mechanics in patients with ARDS? Respir Care . 2016;61(6):876-90.
Lin YJ, Wang YC, Huang HH, Huang CH, Liao MX, Lin PL. Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. J Gastroenterol Hepatol. 2020;35(7):1189-95.
Nelson S, Muzyk AJ, Bucklin MH, Brudney S, Gagliardi JP. Defining the role of dexmedetomidine in the prevention of delirium in the intensive care unit. Biomed Res Int. 2015;2015:635737.
Papazian L, Aubron C, Brochard L, Chiche JD, Combes A, Dreyfuss D, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69.
Pearson SD, Patel BK. Evolving targets for sedation during mechanical ventilation. Curr Opin Crit Care. 2020;26(1):47-52.
Peck TJ, Hibbert KA. Recent advances in the understanding and management of ARDS. F1000Res. 2019;8:F1000.
Prommer E. Midazolam: an essential palliative care drug. Palliat Care Soc Pract. 2020;14:2632352419895527.
Scholten EL, Beitler JR, Prisk GK, Malhotra A. Treatment of ARDS with prone positioning. Chest. 2017;151(1):215-24.
Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373(9678):1874-82.
Shah FA, Girard TD, Yende S. Limiting sedation for patients with acute respiratory distress syndrome - time to wake up. Curr Opin Crit Care . 2017;23(1):45-51.
Sharp C, Millar AB, Medford AR. Advances in understanding of the pathogenesis of acute respiratory distress syndrome. Respiration. 2015;89(5):420-34.
Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377(6):562-72.
Wilson JG, Calfee CS. ARDS subphenotypes: understanding a heterogeneous syndrome. Crit Care. 2020;24(1):102.
Xiao D, Zhang D, Xiang D, Liu QI, Liu Y, Lv L, et al. Effects of fentanyl, midazolam and their combination on immune function and mortality in mice with sepsis. Exp Ther Med . 2015;9(4):1494-500.
Xu Y, Zhang R, Li C, Yin X, Lv C, Wang Y, et al. Dexmedetomidine attenuates acute lung injury induced by lipopolysaccharide in mouse through inhibition of MAPK pathway. Fundam Clin Pharmacol. 2015;29(5):462-71.
Yu X, Li C. Protective effects of propofol on experimental neonatal acute lung injury. Mol Med Rep. 2019;19(5):4507-13.
Zhao J, Yu H, Liu Y, Gibson SA, Yan Z, Xu X, et al. Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2016;311(5):L868-l880.
Zorowitz RD. ICU-Acquired weakness: a rehabilitation perspective of diagnosis, treatment, and functional management. Chest. 2016;150(4):966-71.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
